【内分泌】NET の SSTR2A 発現の免疫組織化学的基準：オクトレオスキャンとの対比

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy

Modern Pathology volume 20, pages1172–1182(2007)

Marco Volante, Maria Pia Brizzi, Antongiulio Faggiano, Stefano La Rosa, Ida Rapa, Anna Ferrero, Gelsomina Mansueto, Luisella Righi, Silvana Garancini, Carlo Capella, Gaetano De Rosa, Luigi Dogliotti, Annamaria Colao, Mauro Papotti

NET で SSTR inhibitor が治療選択となっているが、免疫組織化学染色での SSTR2A の陽性判定基準の元となっている論文である。筆頭著者の名前から一般に Volante の基準と呼ばれている。

Abstract
Typing somatostatin receptor expression in neuroendocrine tumors is of relevance to target somatostatin analogue-based diagnostic approach and treatment. The expanding use of immunohistochemistry to detect somatostatin receptors is to date not paralleled by an accurate methodological setting and standardized interpretation of the results. A multicentric study was designed to compare somatostatin receptor immunohistochemical expression with in vivo scintigraphic data and verify its usefulness in the clinical management of neuroendocrine tumors. After methodological setting by testing different somatostatin receptor antibodies, 107 cases of neuroendocrine tumors with available somatostatin receptor scintigraphy data and pathological material were retrospectively analyzed for somatostatin receptor types 2A, 3 and 5 immunohistochemical expression, and compared with scintigraphic images and, whenever available, with the clinical response to somatostatin analogue treatment. Restricting 'positive cases' to the presence of a membrane pattern of staining, an overall somatostatin receptor type 2A immunohistochemistry/somatostatin receptor scintigraphy agreement of 77% (chi2 test P<0.0001) was reached. Lower concordance ratios were detected in preoperative and metastatic tumor samples, possibly as a consequence of somatostatin receptor expression heterogeneity. Pure somatostatin receptor type 2A cytoplasmic staining showed poor correlation with somatostatin receptor scintigraphy (54% concordance rate). The immunohistochemical detection of somatostatin receptor types 3 and 5, which showed almost exclusively a cytoplasmic pattern, did not improve the concordance with scintigraphic data. In a pilot series, somatostatin receptor type 2A immunohistochemistry correlated with clinical response in 75% of cases. In conclusion, we propose a scoring system for somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors correlated with in vivo data, based on the evidence that only membrane (rather that cytoplasmic) staining should be considered for a reliable, standardized and clinically relevant report.

図は本文より引用。

無料ダウンロード（Modern Pathology）および PubMed のリンク👇

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy - PubMed

代謝・内分泌・NET の目次はこちら👇

【病理医さのーと】メニュー
👉【病理医さのーと】の自己紹介
👉【病理医さのーと】のサイトマップ
👉【SANOTIC ARCHIVES】医療系サイトマップ
 #病理医さのーと #病理診断 #病理学 #医学 #医療 #私の仕事 #いま私にできること #病理医がつなぐ医療の架け橋 #内分泌 #神経内分泌腫瘍 #NET #SSTR #ソマトスタチン受容体 #免疫組織化学 #IHC #免疫染色 #オクトレオチド #octreotide #オクトレオスキャン